12:00 AM
 | 
Nov 16, 2009
 |  BioCentury  |  Emerging Company Profile

Elara: Four legs against hypoxia

Elara Pharmaceuticals GmbH is developing four new chemical classes of orally available hypoxia signaling inhibitors that it thinks could treat cancer more effectively and safely than first generation inhibitors in the clinic.

Elara is collaborating with the myeloma center at UniversitätsKlinikum Heidelberg on IND-enabling studies of an unnamed lead compound to treat multiple myeloma (MM). The company expects to file an IND by the end of 2010 and enter Phase I testing early in 2011.

Most therapeutics targeting hypoxic tumors cells inhibit hypoxia-inducible factor 1 alpha (HIF1A), which plays a key role in the signaling pathway that helps cells survive under low-oxygen conditions such as those found in solid tumors. Elara's compounds are single-digit nanomolar inhibitors of an undisclosed target that is not HIF1A, CEO and...

Read the full 624 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >